PARP1 and ovarian carcinoma: Several treatment strategies have been evaluated in the setting of platinum-resistant ovarian cancer, and treatment associations involving PARP inhibition, antiangiogenic agents, immune checkpoint inhibitors, and chemotherapy have shown promising results.